Skip to main content

IDWeek 2022 Main banner

Tweets by IDWeek 2022

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Back

Veronica Hulstrøm, PhD MD

GSK, Wavre, Belgium, Belgium

Disclosure(s): GlaxoSmithKline Biologicals SA: Employee

Poster(s):

96 - A Candidate Respiratory Syncytial Virus (RSV) Prefusion F Protein Investigational Vaccine (RSVPreF3 OA) Is Immunogenic when Administered in Adults ≥ 60 Years of Age: Results at 6 Months after Vaccination
Thursday, October 20, 2022
12:15 PM – 1:30 PM US ET
119 - Safety and Reactogenicity of an Investigational Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine for Adults ≥ 60 Years of Age (RSVPreF3 OA): an Interim Analysis at 6 Months after Vaccination
Thursday, October 20, 2022
12:15 PM – 1:30 PM US ET
2139 - Immunogenicity, reactogenicity and safety of a Respiratory Syncytial Virus prefusion F (RSVPreF3) candidate vaccine co-administered with the seasonal quadrivalent influenza vaccine in older adults
Saturday, October 22, 2022
12:15 PM – 1:30 PM US ET